TITLE

Ropinirole in the Treatment of Patients With Restless Legs Syndrome: A US-Based Randomized,Double-Blind,Placebo-Controlled Clinical Trial

AUTHOR(S)
Bogan, Richard K.; Fry, June M.; Schmidt, Markus H.; Carson, Stanley W.; Ritchie, Sally Y.
PUB. DATE
January 2006
SOURCE
Mayo Clinic Proceedings;Jan2006, Vol. 81 Issue 1, p17
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: To assess the efficacy, safety, and tolerability of the dopamine agonist ropinlrole in the treatment of patients with moderate to severe primary restless legs syndrome (RLS). PATIENTS AND METHODS: This multicenter, 12-week, double- blind, placebo-controlled, flexible-dose study enrolled US patients and was conducted between September 2003 and May 2004. Patients were randomized to ropinirole or placebo, 0.25-4.0 mg as needed and tolerated, once daily, 1 to 3 hours before bedtime. The primary end point was mean change from baseline to week 12 In International Restless Legs Scale (IRLS) total score. Key secondary efficacy measures included the Clinical Global Impression-Improvement scale. RESULTS: A total of 381 patients were enrolled; 164 (87.7%) of 187 patients randomized to ropinirole and 167 (86.1%) of 194 randomized to placebo completed the study. Significant treatment differences favoring ropinirole, compared with placebo, were observed for change in IRLS total score at week 12 (adjusted mean treatment difference, -3.7; 95% confidence Interval, -5.4 to -2.0; P<.001) and for all 3 key secondary end points: mean change from baseline In IRLS total score at week I and proportion of patients who were much/very much Improved on the Clinical Global Impression Improvement scale at weeks 1 and 12. Ropinirole was associated with significantly greater Improvements in subjective measures of sleep disturbance, quantity, and adequacy; quality of life; and anxiety. Although treatment differences favoring ropinirole in daytime somnolence were observed, they were not statistically significant (P = .10). Ropinirole was generally well tolerated, with an adverse-event profile consistent with other dopamine agonists. CONCLUSION: This study confirms that ropinirole Improves RLS symptoms and subjective measures of sleep, quality of life, and anxiety and that it is generally well tolerated.
ACCESSION #
19800781

 

Related Articles

  • Treatment of Restless Legs Syndrome. Comella, Cynthia // Neurotherapeutics;Jan2014, Vol. 11 Issue 1, p177 

    Restless legs syndrome (RLS) is a common disorder diagnosed by the clinical characteristics of restlessness in the legs associated often with abnormal sensations that start at rest and are improved by activity, occurring with a diurnal pattern of worsened symptoms at night and improvement in the...

  • Ropinirole in the Treatment of Restless Legs Syndrome. Vetrugno, Roberto; Montagna, Pasquale // Clinical Medicine: Therapeutics;2009, Issue 1, p1237 

    Restless Legs Syndrome (RLS) is a neurological disorder characterized by unpleasant sensations in the legs and an irresistible urge to move them to relieve discomfort. Evidence-based guidelines consider dopaminergic therapy to be the mainstay of treatment for RLS. Ropinirole is a modern,...

  • Ropinirole.  // AHFS Consumer Medication Information;Oct2016, p1 

    Ropinirole is used alone or with other medications to treat the symptoms of Parkinson's disease (PD; a disorder of the nervous system that causes difficulties with movement, muscle control, and balance), including shaking of parts of the body, stiffness, slowed movements, and problems with...

  • how can I calm trembling legs?  // Natural Health;Jun2006, Vol. 36 Issue 6, p24 

    The article presents views of various medical personnel on symptoms and treatment options for restless legs syndrome (RLS). Mark Hallett, senior investigator for the National Institute of Neurological Disorders and Stroke, says that one way to treat the condition is with dopamine...

  • Symptomatic treatment of restless legs syndrome. Davis, Kelli; Saunders, Carol S. // Patient Care;Jun2002, Vol. 36 Issue 8, p10 

    Discusses the efficacy of pramipexole, a dopamine receptor agonist, in treating restless legs syndrome (RLS). Information on RLS; Treatment of RLS; Studies showing the efficacy of pramipexole in treating RLS.

  • Distressing sensations. Mason, Mary-Claire // Nursing Standard;4/20/2011, Vol. 25 Issue 33, p23 

    A little-understood condition needs to be taken seriously as its effects can range from irritating to disabling. Mary-Claire Mason reports.

  • GSK wins restless leg race. Iskowitz, Marc // Medical Marketing & Media;Jun2005, Vol. 40 Issue 6, p14 

    This article reports that GlaxoSmithKline PLC's Requip has become the first drug to win the U.S. Food and Drug Administration's approval to treat restless legs syndrome (RLS). Already on the market to treat the symptoms of Parkinson's disease, Requip won approval at lower doses for treating...

  • IRLSSG releases guidelines for restless legs syndrome.  // PharmacoEconomics & Outcomes News;8/1/2013, Issue 684, p3 

    The article reports on the guidelines for the long-term treatment of restless legs syndrome from the International Restless Legs Syndrome Study Group (IRLSSG) which recommends the use of either a dopamine-receptor agonist as first-line treatments of the disease.

  • Gabapentin improved sensory and motor symptoms in the restless legs syndrome. Albanese, Alberto; Filippini, Graziella // ACP Journal Club;Jul/Aug2003, Vol. 139 Issue 1, p17 

    Examines whether gabapentin is more effective than placebo for improving sensory and motor symptoms in patients with the restless legs syndrome (RLS). Main outcome measures; Assessment of clinically relevant outcomes of new drug treatments; Risk for carryover effect.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics